NICE now recommends CYP2C19 testing before prescribing Clopidogrel for stroke/TIA patients, yet many high-risk individuals in private practice still fall outside NHS testing criteria.
This session will cover who should be tested, CYP2C19 variant impact on Clopidogrel response, real-world clinical scenarios, and how rapid private testing can support safe antiplatelet prescribing and reduce preventable cardiovascular and cerebrovascular events.
